Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03476798
Title Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors University of Oklahoma
Indications

endometrial carcinoma

cervix carcinoma

Therapies

Bevacizumab + Rucaparib

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.